Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

BACKGROUND: Anaplastic lymphoma kinase (ALK) fusions need to be accurately and efficiently detected for ALK inhibitor therapy. Fluorescence in situ hybridization (FISH) remains the reference test. Although increasing data are supporting that ALK immunohistochemistry (IHC) is highly concordant with F...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ann Oncol
Auteurs principaux: Takeuchi, K., Togashi, Y., Kamihara, Y., Fukuyama, T., Yoshioka, H., Inoue, A., Katsuki, H., Kiura, K., Nakagawa, K., Seto, T., Maemondo, M., Hida, T., Harada, M., Ohe, Y., Nogami, N., Yamamoto, N., Nishio, M., Tamura, T.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2016
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4684157/
https://ncbi.nlm.nih.gov/pubmed/26487585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv501
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires